Articles tagged with Liver Damage
Alcoholic liver disease is a major public health concern in China, influenced by cultural factors and high alcohol consumption. The disease's increasing prevalence and severe complications highlight the need for comprehensive strategies to manage and prevent ALD.
Significant progress has been made in understanding and managing cholestatic liver diseases, with emerging therapies like OCA, fibrates, and budesonide. Multidisciplinary approaches involving hepatologists, gastroenterologists, and primary care physicians are crucial for improving patient outcomes.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
A new study led by researchers from the University of Pennsylvania School of Medicine developed a novel approach to assess medication-related liver injury. By analyzing real-world health care data, they found that some medications' levels of danger to the liver are being misclassified.
Research found that RAMP1 protects liver cells from damage caused by ischemia-reperfusion injury. The protein inhibited the ERK/YAP pathway, leading to reduced cell death and inflammation. This study highlights RAMP1's potential as a therapeutic target for treating this condition.
Studies found a negative relationship between HBV replication and liver inflammation in HBeAg-positive patients with high viral DNA levels, which shifted to positive relationships for those with low DNA levels or HBeAg-negative status. This interaction suggests a complex relationship between viral replication and liver damage progression.
Researchers found that BTF3L4 overexpression mediates APAP-induced liver injury by inducing inflammation and damaging mitochondrial function. Increased BTF3L4 expression is positively associated with liver injury and may serve as a biomarker.
Researchers have identified a gene responsible for the development of starvation-induced fatty liver in cavefish, which are able to protect their liver due to reduced fat accumulation. This genetic basis has implications for understanding and addressing liver conditions in humans, including Type 2 diabetes and obesity.
Research reveals a dynamic pattern of gene expression in liver fibrosis, with persistent effects even during regression. The study identifies key 'hub' genes that could be developed into biomarkers for future therapies.
The Almodóvar lab is studying the link between HIV and pulmonary hypertension, a condition that increases pressure in lung arteries. By examining the interactions between different cell types and using a humanized mouse model, researchers hope to propose novel therapies to prevent lung diseases in people with HIV.
A nationwide study from Karolinska Institutet found that GLP1 agonists like Ozempic reduce the risk of cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease. Those who continued taking the medication for ten years were half as likely to develop severe liver disease.
Regular NHS Health Checks are associated with reduced risks of dying and developing long-term diseases like dementia and liver cirrhosis. The study analyzed data from 97,204 UK Biobank participants and found that attendees had lower diagnosis rates for these conditions, including a 19% lower rate of dementia diagnosis.
A recent study published in EBioMedicine found that yellow fever virus causes myocardial fibrosis, cardiomyocyte hypertrophy, and vascular endothelium alterations, leading to cardiac conduction system disruption. The research provides new insights into the pathogenesis of YF-associated heart injury.
Researchers found that pattern of drinking is a better indicator of liver disease risk than volume alone, with heavy binge drinking increasing the risk six times. The study also highlights the importance of genetic predisposition and type-2 diabetes in determining liver disease risk.
A new stem cell treatment using mRNA technology from COVID-19 vaccines has shown promise in regenerating liver tissue, potentially reversing chronic and acute liver diseases. The treatment stimulates the natural repair mechanism of the liver by activating specific receptors on stem cells.
Researchers have made significant progress in understanding a pathway contributing to liver fibrosis. Paxillin has been found to play a key role in the activation of hepatic stellate cells, leading to excessive extracellular matrix production and scarring. This discovery holds promise for developing new treatments for liver fibrosis.
Researchers from Columbia University have validated GLS2's ability to promote ferroptosis in murine models. This study suggests that targeting GLS2 may be a potential therapeutic strategy against liver diseases, particularly hepatocellular carcinoma.
A new study found that living donor liver transplant access optimizes the timing of transplant for older, frail cirrhosis patients. Patients with moderate to severe frailty, short stature, and low MELD scores benefited from LDLT, reducing waitlist mortality and improving post-transplant outcomes.
Researchers discovered that the lancet liver fluke takes over an ant's brain, causing them to cling to blades of grass against their will. The parasite controls the ant's behavior to avoid heat, a strategy also used by cattle and deer.
A nationwide study from Karolinska Institutet in Sweden found that close relatives and partners of people with metabolic-associated fatty liver disease (MASLD) are at a higher risk of developing liver cancer and severe liver disease. This suggests that family members could benefit from the same lifestyle advice as patients with MASLD.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A new approach to treating non-alcoholic fatty liver disease (NAFLD) has been discovered, utilizing resistant starch to reduce fat accumulation and inflammation in the liver. The study found that consuming resistant starch daily led to an increase in beneficial gut bacteria, which positively impacted liver health.
Researchers have discovered a novel pathway that minimizes liver injury during transplantation by activating the protective CEACAM1-S version. This protective characteristic is regulated by HIF-1α and can be enhanced using molecular tools and alternative gene splicing, reducing organ injury and improving post-transplant outcomes.
Researchers identify key protein interactions that control the body's immune response during liver transplantation, leading to improved transplant survival rates. The study found that a specific communication pathway between CEACAM1 and TIM-3 proteins plays a crucial role in controlling the immune response.
Hospital admissions for alcohol-related hepatitis increased dramatically during the pandemic, particularly among younger patients and women. Researchers found a 12.4% rise in cases in 2020 compared to 2019 levels.
Researchers investigated premature senescence in biliary atresia and assessed senotherapies. They found that human allogenic liver-derived progenitor cells reduced early markers of senescence and improved liver disease in a preclinical model, providing encouraging results for pediatric biliary cirrhosis treatment.
Researchers found that obese patients with mild traumatic brain injuries had higher levels of inflammatory biomarkers and prolonged symptoms compared to those with healthy body mass indexes. The study suggests that obesity may mediate the inflammatory response and symptoms in mTBI patients.
A clinical trial using DIALIVE, a novel liver dialysis device, demonstrated significant improvements in all main underlying pathophysiological mechanisms of acute-on-chronic liver failure. Treatment resulted in accelerated resolution of ACLF and sustained improvement in biomarkers.
A new substudy of the STEP TEENS trial shows that semaglutide significantly reduces levels of liver enzymes, including alanine aminotransferase (ALT), which are indicators of liver damage. The study found improvements in ALT levels with weight loss of ≥10%.
A research team at Hokkaido University has developed a system to deliver antioxidants to mitochondria in the liver, reducing oxidative stress and damaging caused by ROS. The system, called CoQ10-MITO-Porter, was found to be more effective when downsized particles were used.
Researchers have developed a glycine-based tripeptide that successfully treats nonalcoholic fatty liver disease in non-human primates and mice. The compound, DT-109, reverses fat buildup and prevents scarring by stimulating fatty acid degradation and antioxidant formation.
Researchers developed an ASO treatment that improves bile duct development and prevents fibrosis and cell death in animal models of Alagille syndrome. The study offers a potential therapeutic option for patients with this condition, potentially bypassing the need for liver transplant.
Researchers found that after 96 weeks, some patients achieved loss of detectable HBsAg and reduced liver inflammation levels, indicating functional cure. The study suggests that discontinuing long-term antiviral therapy may be more effective than continuing it for certain patients.
A recent study found that the mitochondrial antioxidant MitoQ can reverse the detrimental effects of HIV and antiretroviral therapy on organs such as the brain, heart, and liver. The researchers used humanized mice infected with HIV and treated them with MitoQ for three months.
Researchers from Kyushu University found that the single mechanosensitive protein VGLL3 induces fibrosis, thickening and scarring tissue. The study suggests targeting this protein could lead to new treatments against fibrosis.
A US FDA mandate to limit acetaminophen dosage in pills combining it with opioids significantly reduced hospitalizations and acute liver failure cases. Researchers found a persistent decline in yearly rates of these cases after the mandate was implemented in 2014.
A new study by Weill Cornell Medicine found that the FDA's mandate to limit opioid-acetaminophen combinations resulted in significant reductions in liver injuries. The mandate, implemented in 2014, limited the dosage of acetaminophen in these drugs, leading to a decline in hospitalizations and acute liver failure cases.
A new study shows that patients with liver cirrhosis have a lower immune response to COVID-19 vaccines, but this does not affect the vaccines' effectiveness. Age, type of vaccine, and viral hepatitis etiology also play a role in immune responses.
A team of researchers from MedUni Vienna has identified the polymeric immunoglobulin receptor (pIgR) as a key player in protecting against alcohol-induced liver damage. The study found that pIgR-mediated secretion of antibodies in the intestines helps to prevent bacterial translocation and inflammation in the liver.
Researchers at Michigan Medicine have developed a new biomarker-based strategy to screen for immune checkpoint inhibitor-induced myocarditis, which can cause muscle damage and liver injury. Early detection of these biomarkers can lead to earlier treatment and improved survival rates.
Research from Rutgers University suggests that high-dose green tea extract may cause liver damage in individuals with specific genetic variations. The study found that two genetic variants, COMT and UGT1A4, were associated with increased liver stress after a year of consuming the supplement.
A new study finds that COVID-19 patients exhibit higher liver stiffness months after infection, indicating possible long-term liver damage. The study also suggests that even pre-pandemic patients showed increased liver stiffness, likely due to changing referral patterns during the pandemic.
Researchers found that a genetic mutation associated with liver disease confers different levels of risk depending on a patient's diabetic status. In diabetic patients, the mutation predisposes them to nonalcoholic fatty liver disease, but in nondiabetic patients, it protects against liver disease.
A study in Japan reveals that universal screening methods for biliary atresia, a rare and severe lung condition in infants, are cost-effective. The research found that stool color card screening and direct bilirubin testing gained significant clinical benefits and saved lives.
A retrospective study of 26,000 patients with cirrhosis found that receiving a third dose of the COVID-19 vaccine reduced overall and severe cases by 80% and 100%, respectively. This suggests that a third dose can overcome vaccine hyporesponsiveness in patients with cirrhosis.
Researchers developed a non-invasive algorithm to identify patients with compensated cirrhosis at highest risk for severe complications. The online calculator uses widely available laboratory parameters and is simple, non-invasive, and cost-effective.
A study identifies a molecule called NIK that promotes the growth of bile duct cells in the liver, leading to scarring and liver fibrosis. Removing NIK or blocking its action with inhibitors may prevent disease progression.
A new Chinese Medical Journal review article elucidates the potential contributors to non-alcoholic fatty liver disease (NAFLD) progression, highlighting the role of bile acid and sphingolipid biology. Researchers summarize current understanding of NAFLD, its progression, and potential therapeutic strategies.
Researchers have developed a new treatment principle that combines DNA-based and protein-based vaccines to stimulate the immune system against both hepatitis B and D viruses. The treatment has been shown to protect cultured cells against HBV and HDV infection, producing high levels of neutralizing antibodies and T-cells.
Researchers have identified Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2) as a key regulator in the development and progression of nonalcoholic steatohepatitis. IGF2BP2 overexpression was found to induce liver steatosis, inflammation, and injury in healthy mice, while knockdown improved NASH pathogenesis.
A new study suggests that acetate produced by the liver diffuses into the intestines, supporting bacterial growth and causing imbalanced microbiota. This imbalance does not appear to play a major role in alcoholic liver disease risk.
The study investigated the effects of combined endocrine-disrupting chemicals (EDCs) on liver function and metabolic homeostasis in mice models. Significant changes were observed at high EDC exposure levels, including liver weight increase, lipid buildup, and elevated blood glucose levels.
Individualized, comprehensive treatment approaches and risk stratification of patients are crucial for effective treatment of MAFLD. Lifestyle modifications and pharmaceutical therapeutics combining to treat the condition.
Researchers found that lactating mothers expose their pups to triclosan, leading to early signs of liver damage that can progress to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Exposure to triclosan in early life may lay the groundwork for future development of fatty liver disease.
The new grant aims to address structural racism and discrimination affecting Asian-Americans with chronic hepatitis B virus infection and liver cancer. Researchers will examine factors such as socio-historical hardship, segregation, and mistrust of the health system to improve quality of care.
A study found that Dragon's Blood alleviates brain damage, hematopoietic dysfunction, and gastrointestinal damage caused by radiation in rats. The compound regulates metabolism and redox homeostasis to protect the liver from damage.
Youth substance use declined during the COVID-19 pandemic, as teens had limited access to peers and substances due to stay-at-home orders. This reduced risk of substance use is attributed to increased social isolation from peers, which may have a negative impact on mental health.
A novel study has identified metabolic defects, impaired protein secretion, and altered phosphoproteomic signatures in alcohol-associated cirrhosis and hepatitis. These findings may lead to the development of new diagnostic and therapeutic approaches for a disease with limited treatment options.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
Research finds that excessive mitochondrial damage caused by alcohol exposure can lead to chronic liver disease. Mitochondrial depolarization triggers mitophagy, a process removing damaged mitochondria; however, constant removal causes additional liver tissue damage.